Skip to Content

'
Xuelin Huang, Ph.D.

Present Title & Affiliation

Primary Appointment

Professor, Department of Biostatistics, Division of Quantitative Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

2002 University of Michigan, Ann Arbor, MI, PHD, Biostatistics
1997 Texas A & M University, College Station, TX, MS, Mathematics
1994 Peking University, Beijing, China, BS, Probability & Statistics

Experience/Service

Academic Appointments

Associate Professor, Department of Biostatistics, Division of Quantitative Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2007-8/2013
Assistant Professor, Department of Biostatistics, Division of Quantitative Sciences, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 9/2002-8/2007
Research Assistant, Department of Biostatistics, University of Michigan, Ann Arbor, MI, 9/2000-7/2002
Graduate Assistant, Department of Mathematics, Texas A & M University, College Station, TX, 9/1995-5/1997

Honors and Awards

2001 Best Student Paper Award, Biopharmaceutical Section of the American Statistical Association

Selected Publications

Peer-Reviewed Original Research Articles

1. Yi M, Luo S. Huang X, Hunt K. A Bayesian Model for Misclassified Binary Outcomes and Correlated Survival Data with Applications to Breast Cancer. Statistics in Medicine. In Press.
2. Choi S, Huang X. A general class of semiparametric transformation frailty models for nonproportional hazards survival data. Biometrics. In Press.
3. Cai G, Li H, Lu Y, Huang X, Lee J, Muller P, Ji Y, Liang S. Accuracy of RNA-Seq and its dependence on sequencing depth. BMC Bioinformatics. In Press.
4. Carter B, Qiu Y, Huang X, Diao L, Zhang N, Coombes K, Mak D, Konopleva M, Cortes J, Kantarjian H, Mills G, Andreeff M, Kornblau S. Surviving is highly expressed in leukemic stem cells and predicts poor clinical outcomes in AML. Blood. In Press.
5. Rao X, Lai D, Huang X. A new method for quantitative real-time polymerase chain reaction data analysis. Comput Biol, 7/2013. e-Pub 7/2013. PMID: 23841653.
6. Nazha A, Kantarjian H, Ravandi F, Huang X, Choi S, Garcia-Manero G, Jabbour E, Borthakur G, Kadia T, Konopleva M, Cortes J, Ferrajoli A, Kornblau S, Daver N, Pemmaraju N, Andreeff M, Estrov Z, Du M, Brandt M, Faderl S. Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤ 60 years with newly diagnosed acute myeloid leukemia (AML). Am J Hematol, 7/2013. PMID: 23877926.
7. Choi S, Huang X, Chen YH. A class of semiparametric transformation models for survival data with a cured proportion. Lifetime Data Analysis, 6/2013. PMID: 23760878.
8. Surena F. Matin, Janice N. Cormier, John F. Ward, Louis L. Pisters, Christopher G. Wood, Colin P.N. Dinney, Richard E. Royal, Xuelin Huang and Curtis A. Pettaway. Phase 1 prospective evaluation of the oncological adequacy of robotic assisted video-endoscopic inguinal lymphadenectomy in patients with penile carcinoma. BJU International 111(4b):1068-74, 4/2013.
9. Huang X, Ning J. Analysis of multi-stage treatments for recurrent diseases. Stat Med. e-Pub 7/24/2012. PMID: 22826139.
10. Huang X, Cortes J, Kantarjian H. Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer 118(12):3123-7, 6/15/2012. e-Pub 1/31/2012. PMCID: PMC3342429.
11. Kadia TM, Borthakur G, Garcia-Manero G, Faderl S, Jabbour E, Estrov Z, York S, Huang X, Pierce S, Brandt M, Koller C, Kantarjian HM, Ravandi F. Final results of the phase II study of rabbit anti-thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony-stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome. Br J Haematol 157(3):312-20, 5/2012. e-Pub 2/24/2012. PMID: 22360602.
12. Kantarjian H, O'Brien S, Jabbour E, Garcia-Manero G, Quintas-Cardama A, Shan J, Rios MB, Ravandi F, Faderl S, Kadia T, Borthakur G, Huang X, Champlin R, Talpaz M, Cortes J. Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. Blood 119(9):1981-7, 3/1/2012. e-Pub 1/6/2012. PMCID: PMC3311242.
13. Faderl S, Ravandi F, Huang X, Wang X, Jabbour E, Garcia-Manero G, Kadia T, Ferrajoli A, Konopleva M, Borthakur G, Burger J, Feliu J, Kantarjian HM. Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients. Cancer. e-Pub 1/26/2012. PMID: 22282348.
14. Kojima K, McQueen T, Chen Y, Jacamo R, Konopleva M, Shinojima N, Shpall E, Huang X, Andreeff M. p53 activation of mesenchymal stromal cells partially abrogates microenvironment-mediated resistance to FLT3 inhibition in AML through HIF-1α-mediated down-regulation of CXCL12. Blood 118(16):4431-9, 10/20/2011. e-Pub 8/25/2011. PMCID: PMC3204912.
15. Chen Y, Cortes J, Estrov Z, Faderl S, Qiao W, Abruzzo L, Garcia-Manero G, Pierce S, Huang X, Kebriaei P, Kadia T, De Lima M, Kantarjian H, Ravandi F. Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantation. J Clin Oncol 29(18):2507-13, 6/20/2011. e-Pub 5/9/2011. PMID: 21555694.
16. Yuan Y, Huang X, Liu S. A Bayesian response-adaptive covariate-balanced randomization design with application to a leukemia clinical trial. Stat Med 30(11):1218-29, 5/2011. e-Pub 3/2011. PMCID: PMC3086983.
17. Sivina M, Hartmann E, Kipps TJ, Rassenti L, Krupnik D, Lerner S, LaPushin R, Xiao L, Huang X, Werner L, Neuberg D, Kantarjian H, O'Brien S, Wierda WG, Keating MJ, Rosenwald A, Burger JA. CCL3 (MIP-1a) plasma levels and the risk for disease progression in chronic lymphocytic leukemia. Blood 117(5):1662-9, 2/3/2011. e-Pub 11/29/2010. PMCID: PMC3318778.
18. Ning J, Huang X. Response-Adaptive Randomization for Clinical Trials with Adjustment for Covariate Imbalance. Stat Med 29(17):1761-8, 7/30/2010. PMCID: PMC2911996.
19. Walter RB, Kantarjian HM, Huang X, Pierce SA, Sun Z, Gundacker HM, Ravandi F, Faderl SH, Tallman MS, Appelbaum FR, Estey EH. Effect of Complete Remission and Responses Less Than Complete Remission on Survival in Acute Myeloid Leukemia: A Combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M.D. Anderson Cancer Center Study. J Clin Oncol 28(10):1766-71, 4/1/2010. e-Pub 2/16/2010. PMCID: PMC2849766.
20. Shen L, Kantarjian H, Guo Y, Lin E, Shan J, Huang X, Berry D, Ahmed S, Zhu W, Pierce S, Kondo Y, Oki Y, Jelinek J, Saba H, Estey E, Issa JP. DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol 28(4):605-13, 2/1/2010. e-Pub 12/28/2009. PMCID: PMC2815995.
21. Borthakur G, Huang X, Kantarjian H, Faderl S, Ravandi F, Ferrajoli A, Torma R, Morris G, Berry D, Issa JP. Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes. Leuk Lymphoma 51(1):73-8, 1/2010. PMCID: PMC2876330.
22. Santos FP, Faderl S, Garcia-Manero G, Koller C, Beran M, O'Brien S, Pierce S, Freireich EJ, Huang X, Borthakur G, Bueso-Ramos C, de Lima M, Keating M, Cortes J, Kantarjian H, Ravandi F. Adult Acute Erythroleukemia: An analysis of 91 patients treated at a single institution. Leukemia 23(12):2275-80, 12/2009. e-Pub 9/10/2009. PMID: 19741728.
23. Ravandi F, Aribi A, O'Brien S, Faderl S, Jones D, Ferrajoli A, Huang X, York S, Pierce S, Wierda W, Kontoyiannis D, Verstovsek S, Pro B, Fayad L, Keating M, Kantarjian H. Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms. J Clin Oncol 27(32):5425-30, 11/10/2009. e-Pub 10/5/2009. PMID: 19805674.
24. Konoplev S, Huang X, Drabkin HA, Koeppen H, Jones D, Kantarjian HM, Garcia-Manero G, Chen W, Medeiros LJ, Bueso-Ramos CE. Cytoplasmic localization of nucleophosmin in bone marrow blasts of acute myeloid leukemia patients is not completely concordant with NPM1 mutation and is not predictive of prognosis. Cancer 115(20):4737-44, 10/15/2009. PMID: 19637342.
25. Garg R, Faderl S, Garcia-Manero G, Cortes J, Koller C, Huang X, York S, Pierce S, Brandt M, Beran M, Borthakur G, Kantarjian H, Ravandi F. Phase II study of rabbit anti-thymocyte globulin, cyclosporine and granulocyte colony-stimulating factor in patients with aplastic anemia and myelodysplastic syndrome. Leukemia 23(7):1297-302, 7/2009. e-Pub 2/26/2009. PMID: 19242494.
26. Huang X, Ning J, Li Y, Estey E, Issa JP, Berry DA. Using short-term response information to facilitate adaptive randomization for survival clinical trials. Stat Med 28(12):1680-9, 5/30/2009. PMCID: PMC2883264.
27. Liu L, Huang X. Joint analysis of correlated repeated measures and recurrent events processes in the presence of death, with application to an AIDS study. Journal of the Royal statistical Society, Series C (Applied statistics) 58(1):65-81, 2009.
28. Huang X, Zhang N. Regression Survival Analysis with an Assumed Copula for Dependent Censoring: A Sensitivity Analysis Approach. Biometrics 64(4):1090-9, 12/2008. e-Pub 2/11/2008. PMID: 18266895.
29. Faderl S, Ferrajoli A, Wierda W, Huang X, Verstovsek S, Ravandi F, Estrov Z, Borthakur G, Kwari M, Kantarjian HM. Clofarabine combinations as acute myeloid leukemia salvage therapy. Cancer 113(8):2090-6, 10/15/2008. PMID: 18756533.
30. Faderl S, Ravandi F, Huang X, Garcia-Manero G, Ferrajoli A, Estrov Z, Borthakur G, Verstovsek S, Thomas DA, Kwari M, Kantarjian HM. A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 112(5):1638-45, 9/1/2008. e-Pub 6/18/2008. PMID: 18565853.
31. Liu L, Huang X. The use of Gaussian quadrature for estimation in frailty proportional hazards models. Stat Med 27(14):2665-83, 6/2008. PMID: 17910008.
32. Anaya DA, Xing Y, Feng L, Huang X, Camacho LH, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Cormier JN. Adjuvant high-dose interferon for cutaneous melanoma is most beneficial for patients with early stage III disease. Cancer 112(9):2030-7, 5/1/2008. PMID: 18320602.
33. Garcia-Manero G, Shan J, Faderl S, Cortes J, Ravandi F, Borthakur G, Wierda WG, Pierce S, Estey E, Liu J, Huang X, Kantarjian H. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia 22(3):538-43, 3/2008. e-Pub 12/13/2007. PMID: 18079733.
34. Kantarjian H, O'Brien S, Shan J, Huang X, Garcia-Manero G, Faderl S, Ravandi-Kashani F, Verstovsek S, Beth Rios M, Cortes J. Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions? Cancer 112(4):837-45, 2/15/2008. PMID: 18085610.
35. O'Brien S, Ravandi F, Riehl T, Wierda W, Huang X, Tarrand J, O'Neal B, Kantarjian H, Keating M. Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy. Blood 111(4):1816-9, 2/15/2008. e-Pub 11/26/2007. PMID: 18039954.
36. Liu L, Huang X, O'Quigley J. Analysis of longitudinal data in the presence of informative observational times and a dependent terminal event, with application to medical cost data. Biometrics 64(3). e-Pub 12/20/2007. PMID: 18162110.
37. Huang X, Liu L. A Joint Frailty Model for Survival and Gap Times Between Recurrent Events. Biometrics 63(2):389-97, 6/2007. PMID: 17688491.
38. Huang X, Biswas S, Oki Y, Issa JP, Berry DA. A Parallel Phase I/II Clinical Trial Design for Combination Therapies. Biometrics 63(2):429-36, 6/2007. PMID: 17688495.
39. Konoplev S, Rassidakis GZ, Estey E, Kantarjian H, Liakou CI, Huang X, Xiao L, Andreeff M, Konopleva M, Medeiros LJ. Overexpression of CXCR4 Predicts Adverse Overall and Event-Free Survival in Patients with Unmutated FLT3 Acute Myeloid Leukemia with Normal Karyotype. Cancer 109(6):1152-6, 3/15/2007. PMID: 17315232.
40. Kantarjian HM, O'Brien S, Huang X, Garcia-Manero G, Ravandi F, Cortes J, Shan J, Davisson J, Bueso-Ramos CE, Issa JP. Survival Advantage with Decitabine Versus Intensive Chemotherapy in Patients with Higher Risk Myelodysplastic Syndrome: Comparison with Historical Experience. Cancer 109(6):1133-7, 3/2007. PMCID: PMC2952542.
41. Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O'Brien S, Cortes J, Faderl S, Bueso-Ramos C, Ravandi F, Estrov Z, Ferrajoli A, Wierda W, Shan J, Davis J, Giles F, Saba HI, Issa JP. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 109(1):52-7, 1/1/2007. e-Pub 8/1/2006. PMID: 16882708.
42. Huang X, Cormier JN, Pisters PW. Estimation of the Causal Effects on Survival of Two-Stage Nonrandomized Treatment Sequences for Recurrent Diseases. Biometrics 62(3):901-9, 9/2006. PMID: 16984334.
43. Ravandi F, Jorgensen JL, O'Brien SM, Verstovsek S, Koller CA, Faderl S, Giles FJ, Ferrajoli A, Wierda WG, Odinga S, Huang X, Thomas DA, Freireich EJ, Jones D, Keating MJ, Kantarjian HM. Eradication of minimal residual disease in hairy cell leukemia. Blood 107(12):4658-62, 6/15/2006. e-Pub 2/23/2006. PMID: 16497968.
44. Cormier JN, Xing Y, Feng L, Huang X, Davidson L, Gershenwald JE, Lee JE, Mansfield PF, Ross MI. Metastatic Melanoma to Lymph Nodes in Patients with Unknown Primary Sites. Cancer 106(9):2012-20, 5/1/2006. PMID: 16568458.
45. Huang X, Strawderman RL. A Note on Breslow Estimator for Survival Functions. Journal of Nonparametric Statistics 18(1):45-6, 2006. PMID: Not in PubMed.
46. Huang X, Biswas S, Estey EH, Berry DA. Building and validating a prognostic index for biomarker studies. Cancer Biomark 2(3-4):97-101, 2006. PMID: 17192064.
47. Shen Y, Huang X. Nonparametric Estimation of Asymptomatic Duration from a Randomized Prospective Cancer Screening Trial. Biometrics 61(4):992-9, 12/2005. PMID: 16401272.
48. Phongkitkarun S, Kobayashi S, Varavithya V, Huang X, Curley SA, Charnsangavej C. Bile Duct Complications of Hepatic Arterial Infusion Chemotherapy Evaluated by Helical CT. Clin Radiol 60(6):700-9, 6/2005. PMID: 16038698.
49. Cormier JN, Huang X, Xing Y, Thall PF, Wang X, Benjamin RS, Pollock RE, Antonescu CR, Maki RG, Brennan MF, Pisters PW. Cohort Analysis of Patients with Localized, High-Risk Extremity Soft Tissue Sarcoma Treated at Two Cancer Centers: Chemotherapy-Associated Outcomes. J Clin Oncol 22(22):4567-74, 11/15/2004. PMID: 15542808.
50. Liu L, Wolfe RA, Huang X. Shared Frailty Model for Recurrent Events and a Terminal Event. Biometrics 60(3):747-56, 9/2004. PMID: 15339298.
51. Huang X, Wolfe RA, Hu C. A Test for Informative Censoring in Clustered Survival Data. Stat Med 23(13):2089-107, 7/15/2004. PMID: 15211605.
52. Rosen DG, Huang X, Deavers MT, Malpica A, Silva EG, Liu J. Validation of Tissue Microarray Technology in Ovarian Carcinoma. Mod Pathol 17(7):790-7, 7/2004. PMID: 15073602.
53. Harrison RV, Janz NK, Wolfe RA, Tedeschi PJ, Stross JK, Huang X, McMahon LF, Jr. Characteristics of Primary Care Physicians and Their Practices Associated with Mammography Rates for Older Women. Cancer 98(9):1811-21, 11/2003. PMID: 14584062.
54. Chang KC, Huang X, Medeiros LJ, Jones D. Germinal Center-Like Versus Undifferentiated Stromal Immunophenotypes in Follicular Lymphoma. J Pathol 201(3):404-12, 11/2003. PMID: 14595752.
55. Harrison RV, Janz NK, Wolfe RA, Tedeschi PJ, Huang X, McMahon LF, Jr. Five-Year Mammography Rates and Associated Factors for Older Women. Cancer 97(5):1147-55, 3/2003. PMID: 12599219.
56. Harrison RV, Janz NK, Wolfe RA, Tedeschi PJ, Chernew M, Stross JK, Huang X, McMahon LF, Jr. Personalized Letter Increases Mammography Among Long-Term Noncompliant Medicare Beneficiaries: A Randomized Trial. Medical Care 41(3):375-85, 3/2003. PMID: 12618641.
57. Huang X, Wolfe RA. A Frailty Model for Informative Censoring. Biometrics 58(3):510-20, 9/2002. PMID: 12229985.

Grant & Contract Support

Title: Targeting the leukemia microenvironment by CXCR4 inhibition in stem cell transplantation for AML
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Marina Konopleva
Duration: 3/1/2009 - 2/28/2012
 
Title: Effective Survellance Strategies for Melanoma Patients
Funding Source: NIH/NCI
Role: Collaborator
Principal Investigator: Janice Cormier
Duration: 12/7/2007 - 11/30/2011
 
Title: Therapy of AML (PC-C2)
Funding Source: NIH/NCI
Role: Co-Director of Biostatistics Core
Principal Investigator: Michael Andreeff
Duration: 9/20/2007 - 8/31/2012
 
Title: New Approaches to the Biology and Treatment of Myelodysplastic Syndromes (MDS) (PC-C)
Funding Source: NIH/NCI
Role: Co-Investigator
Principal Investigator: Hagop Kantarjian
Duration: 6/21/2005 - 5/31/2011

Last updated: 9/10/2013